May 13, 2022 – A literature review in Harvard Review of Psychiatry indicates that, while transcranial electrical stimulation (tES) has rarely been used in treating visual hallucinations (VH) among patients with psychiatric disorders, recent advances in neuroimaging technology show promise in helping tES to more effectively treat VH in psychiatric disorders where VH are a core symptom. The journal is published in the Lippincott portfolio by Wolters Kluwer.
tES is a non-invasive brain stimulation (NIBS) technique that delivers a weak direct or alternating electric current via electrodes placed on the scalp. Nowadays, modern tES devices are equipped with smaller electrodes that can be affixed to more spots on the cranium and provide a more targeted approach to neural network manipulation, enhancing reliability and reproducibility. “Neuroimaging advances, clinical neuroscience developments such as the identification of brain regions causally involved in VH, and personalized NIBS approaches that improve anatomical targeting” may provide a sound foundation for subsequent research on using VH, according to Paulo Lizano, MD, PhD, Beth Israel Deaconess Medical Center, in a Perspectives article published in the May/June issue of the Harvard Review of Psychiatry.
More accurate anatomical measurements lead to better targeting of brain areas that impact visual function.
Although tES has been shown to improve anxiety and bipolar depression, as well as auditory hallucinations and cognition in schizophrenia, few tES trials on VH have been performed with psychiatric populations or with patients with neurological disorders such as Parkinson’s disease, Lewy body dementia, stroke, brain tumors, seizures, or migraines. Currently, antipsychotic, anti-serotonergic, or anti-cholinergic medications are the most common form of treatment for VH in many neuropsychiatric disorders, but there are often not sufficient for targeting VH symptoms.
One case study that Lizano and his co-authors identified during their review as relevant to informing future research involves a 26-year-old female with a ten-year history of recurrent major depressive episodes who experienced daily complex, burdensome VH. After receiving twice-daily transcranial direction current stimulation (tDCS), a form of tES, for five days, she no longer experienced continuous VH, and the most intrusive hallucinations no longer occurred. A 31-year-old male with schizophrenia experiencing refractory VH underwent a three-week tDCS regimen, resulting in a 29% reduction in general, 38% reduction in positive, and 27% reduction in negative, symptoms. However, a clinical trial of Lewy body dementia patients who were treated with tDCS over a four-day period exhibited no reduction in the severity of duration of VH. It’s important to note that large-scale clinical trials have yet to be conducted in patients experiencing VH.
Despite the dearth of studies in the literature, recent advances in neuroimaging technology suggest that future studies can implicate a causal relationship between tES and VH treatment. Improvements in scalp-based targeting offers potential for application in NIBS trials involving VH. Lesion network mapping (LNM) studies that specifically identify targets to the visual cortex may also help.
In addition, individualized modeling techniques and advanced electrical field modeling, though still in their infancy, are a logical next step for larger tES investigations targeting brain regions implicating VH in psychiatric patients. Other promising tES techniques include modulating the retina or optic nerve.
These techniques, combined with meaningful clinical interviews and simulations of behavioral, sensory, and cognitive tasks, can create a “unique multimodal neuroimaging-NIBS approach” to anatomical targeting that can improve how researchers influence visual activity and deliver more effective treatment for psychiatric patients with visual hallucinations.
Click here to read “An Integrated Neuroimaging Approach to Inform Transcranial Electrical Stimulation Targeting in Visual Hallucinations“
About Harvard Review of Psychiatry
The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer-reviewed and not industry sponsored. It is the property of President and Fellows of Harvard College and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals.
Articles encompass all major issues in contemporary psychiatry, including (but not limited to) neuroscience, psychopharmacology, psychotherapy, history of psychiatry, and ethics. In addition to scholarly reviews, perspectives articles, and columns, the journal includes a Clinical Challenge section that presents a case followed by discussion and debate from a panel of experts.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
Harvard Review of Psychiatry